Business
Immunic to Participate in Investor and Scientific Conferences in August
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small
About this update from Immunic, Inc.
[{"type":"text","content":"NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in August:\nAugust 8-9: 2023 Wedbush PacGrow Healthcare Conference. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in one-on-one investor meetings at this conference in New York.August 20-24: 16th International Congress of Neuroimmunology (ISNI). Evelyn Peelen, Ph.D., Senior Manager Translational Pharmacology at Immunic, will present preclinical data showing vidofludimus calcium's potent activation of nuclear receptor related 1 (Nurr1), which may provide neuroprotective benefits in patients with multiple sclerosis, at this congress in Quebec, Canada. The poster presentation will be accessible on the \"Events and Presentations\" section of Immunic's website at: https://ir.imux.com/events-and-presentations.Title: Vidofludimus Calcium, an Orally Available DHODH Inhibitor in Phase 3 Clinical Trials for Multiple Sclerosis, Potently Activates NURR1Abstract Number: 252Poster Session: Emerging therapies for neuroinflammatory conditionsDate: Wednesday, August, 23, 2023Time: 4:15 – 6:15 pm ETAbout Immunic, Inc.Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's lead development program, vidofludimus calcium (IMU-838), is currently in phase 3 and phase 2 clinical trials for the treatment of relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in phase 2 clinical trials in patients suffering from relapsing-remitting multiple sclerosis and moderate-to-severe ulcerative colitis. Vidofludimus calcium combines neuroprotective effects, through its mechanism as a first-in-class nuclear receptor related 1 (Nurr1) activator, with additional anti-inflammatory and anti-viral effects, by selectively inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended to restore intestinal barrier function and regenerate bowel epithelium, which could potentially be appli...